Our goal is to become a fully-integrated biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs that may address areas of significant unmet clinical needs. Our vision is to leverage our advanced drug discovery capabilities to exploit cytoskeletal pharmacology for the discovery, development and commercialization of drugs with clinically novel mechanisms of action. This vision translates into functional strategies that are focused towards minimizing business risk and maximizing our opportunities for success to create long-term benefits for patients. These strategies are defined by functional areas as follows:
Research: To manage technical and financial risk through strategically building redundancies and breadth in all key programs to increase the likelihood of success in each area of research. Details
Clinical Development: To move multiple candidates rapidly into human testing, to conduct rigorous and extensive clinical trials programs and to then execute on the most efficient registration strategy intended to maximize the probability of bringing drug candidates to market. Details
Commercial Planning: To commercialize proprietary pharmaceuticals with focus on therapeutic areas where high clinical unmet needs in concentrated and tractable market segments still exist to improve the lives of patients and ensure a higher return on commercialization. Details
Partnerships: To selectively establish key alliances, retaining key measures of control, flexibility and economic participation, to increase the likelihood that our drug candidates will successfully reach patients in need. Details
Annual corporate planning begins with a strategic planning process that involves all components of the organization. Each year our goal is to critically evaluate our prior year’s ten-year corporate plan, including reassessing the extensive financial analyses and detailed portfolio timelines. Each year, we revisit and critically analyze key scenarios then confronting the organization. By developing and constantly revisiting these scenarios, our team can prospectively identify business risks and potential hurdles thereby allowing the company to more proactively identify actions to mitigate those risks. The end result is a blueprint aimed at ensuring that our organization has thoroughly vetted the strategy and that all risks are identified and then minimized, as best we can, to increase the likelihood of success for our drug candidates and Cytokinetics’ long-term sustainability and durability.